Skip to main content
Robert Towarnicki

Robert Towarnicki, MS

President & CEO, SIRPant Immunotherapeutics Inc.
United States
Robert J. Towarnicki, President & CEO has over 40 years of experience, serving as President of six biotech companies and raised over $400 Million USD for those companies developing: small molecule pharmaceuticals; biologicals, PMA and 510k medical devices; diagnostic assays; and laboratory services. Mr. Towarnicki served as: Interim President of Royer Biomedical Inc.; Interim President of ExSar Corporation; President and Chief Executive Officer of Nucleonics, Inc., an RNAi therapeutics company; Chairman, President and Chief Executive Officer of Cell Pathways, Inc. (NASDAQ: CLPA), a small molecule cancer prevention and therapeutics company; and President and Chief Operating Officer of Integra Life Sciences Corporation (NASDAQ: IART), a medical device company focused on tissue regeneration technologies. Earlier experience includes: General Manager of Focus Technologies, a privately held esoteric disease reference laboratory; Vice President of Product Development and Operations for Collagen Corporation; Plant Manager for Pfizer Pharmaceuticals and ten years of increasing management responsibility in parenteral operations for Merck & Co. Mr. Towarnicki earned a BS and MS in Biology from Villanova University and has served on the Board of Directors of multiple public and private companies as well as the Biotechnology Industry Organization (BIO) and Lifesciences PA.

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.